• Contact Us
GI Dynamics
  • Home
  • EndoBarrier
  • Company
    • Who We Are
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Investors
    • Overview
    • News & Events
    • Stock Information
    • Financial Information
    • Corporate Governance
    • Investor Resources
  • Press
    • Press Releases
    • GID in the Media
    • Publications & Abstracts
Select Page

IK+EM Study Released at EASD Shows Similar Outcomes Between Gastric Plication and EndoBarrier

by Janell Shields | Sep 24, 2017 | Press Releases

LISBON, PORTUGAL — 25 September 2017 — GI Dynamics®, Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, announces that new data has been released...

GI Dynamics Appoints Juliet Thompson to Company’s Board of Directors

by Janell Shields | Aug 22, 2017 | Press Releases

BOSTON and SYDNEY— 23 August 2017— GI Dynamics® Inc. (ASX:GID), a medical device company that commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity announces the appointment of medical and financial...

GI Dynamics Welcomes New Members to Its Scientific Advisory Board

by Janell Shields | Aug 13, 2017 | Press Releases

BOSTON and SYDNEY — 14 August 2017 — GI Dynamics® Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, welcomed new members to the GI Dynamics...

GI Dynamics to Provide Shareholder Update on 2017 Second Quarter Results

by Janell Shields | Aug 9, 2017 | Press Releases

BOSTON and SYDNEY – 10 August 2017 – GI Dynamics® Inc. (ASX: GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, announces it will update investors on 2017...

GI Dynamics Selects Proven Process Medical Devices as Contract Manufacturer

by Janell Shields | Jul 25, 2017 | Press Releases

BOSTON and SYDNEY – 26 July 2017 – GI Dynamics® Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, today announced the selection of Proven Process...

GI Dynamics Announces Additional Members to Its Scientific Advisory Board

by Janell Shields | Jun 20, 2017 | Press Releases

BOSTON and SYDNEY —  20 June 2017 — GI Dynamics® Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity announced additional members of the GI Dynamics...
Page 10 of 39« First«...89101112...2030...»Last »

Press Releases

  • Exercise of Tranche 2 Warrants by Crystal Amber and Appendix 3B

    October 4, 2019
    BOSTON and SYDNEY — 4 October 2019 — GI Dynamics® …
  • Variation of CEO Employment Terms, Issue of Options and Corporate Presentation Update

    September 20, 2019
    BOSTON and SYDNEY — 20 September 2019 AEST — GI …
  • GI Dynamics Announces Worldwide EndoBarrier Registry Data for 871 Patients Presented at EASD 2019

    September 19, 2019
    BOSTON and SYDNEY — 20 September 2019 — GI Dynamics® …

Videos

  • How EndoBarrier Works

    How EndoBarrier Works

    June 24, 2019
    EndoBarrier: Non-surgical Treatment for Patients with Type 2 Diabetes and …
  • Maintenance of Efficacy after EndoBarrier

    Maintenance of Efficacy after EndoBarrier

    July 28, 2017
    UK First NHS EndoBarrier Service – Dr. Bob Ryder June …
  • BBC News Item

    BBC News Item

    January 4, 2017
    EndoBarrier treatment for diabetes & obesity following 1 year results …
  • Home
  • EndoBarrier
  • Company
    • Who We Are
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Investors
    • Overview
    • News & Events
    • Stock Information
    • Financial Information
    • Corporate Governance
    • Investor Resources
  • Press
    • Press Releases
    • GID in the Media
    • Publications & Abstracts
  1. Copyright Info
  2. Terms of Use
  3. Privacy Policy
  4. Patents
  5. Careers

 

CAUTION: EndoBarrier is not approved for sale in the European Union or in the United States and is limited by Federal (US) Law to investigational use only. 
 


GI Dynamics
320 Congress Street 
3rd Floor
Boston, MA 02210

  • Home
  • EndoBarrier
  • Company
  • Investors
  • Press

Designed by Elegant Themes | Powered by WordPress

This website uses cookies to provide you with the best browsing experience.

Find out more or adjust your settings.

GI Dynamics
Powered by GDPR plugin
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.